Dianthus Competitors

Stocks . USA . 
Stock . Dianthus Therapeutics
DNTH Stock   47.48  2.44  4.89%   
Dianthus Therapeutics competes with Enliven Therapeutics, Taysha Gene, Sana Biotechnology, ATAI Life, and Nektar Therapeutics; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Dianthus Therapeutics competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Dianthus Therapeutics to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Dianthus Therapeutics Correlation with its peers.
For more detail on how to invest in Dianthus Stock please use our How to Invest in Dianthus Therapeutics guide.

Dianthus Therapeutics vs Tourmaline Bio Correlation

Moving together with Dianthus Stock

  0.63ENGN enGene Holdings CommonPairCorr

Moving against Dianthus Stock

  0.6ABP Abpro HoldingsPairCorr
  0.6LYRA Lyra TherapeuticsPairCorr
  0.57KURA Kura OncologyPairCorr
  0.47DWTX Dogwood TherapeuticsPairCorr
  0.39GNLX Genelux CommonPairCorr
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Dianthus Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
44.5748.3552.13
Details
Intrinsic
Valuation
LowRealHigh
43.0759.3263.10
Details

Dianthus Therapeutics Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Dianthus Therapeutics and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Dianthus and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Dianthus Therapeutics does not affect the price movement of the other competitor.

High positive correlations

OCS
+ 0.64
ELVN
ATAI
+ 0.63
TSHA
OCS
+ 0.62
ANAB
SANA
+ 0.59
TSHA
IMTX
+ 0.52
NKTR
ATAI
+ 0.51
SANA
  

High negative correlations

TSHA
- 0.56
ELVN
OCS
- 0.5
NKTR
ANAB
- 0.44
NKTR
IMTX
- 0.42
OCS
OCS
- 0.38
ATAI
NKTR
- 0.36
SANA

Risk-Adjusted Indicators

There is a big difference between Dianthus Stock performing well and Dianthus Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Dianthus Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
ELVN  3.91  0.86  0.19  11.90  3.67 
(4.48)
 8.88 
(6.94)
 54.92 
TSHA  3.45  0.19  0.05  0.21  3.95 
(3.68)
 7.57 
(6.86)
 21.14 
SANA  4.37 (0.13) 0.00  0.02  4.63 
(5.63)
 12.59 
(7.71)
 28.66 
ATAI  2.82 (0.19) 0.00 (0.12) 0.00 
 0.00 
 5.77 
(5.54)
 15.30 
NKTR  4.75  0.62  0.11  1.37  4.90 
(5.47)
 8.03 
(7.77)
 32.58 
ANAB  2.58  0.84  0.24  14.92  2.63 
(2.97)
 6.60 
(5.26)
 17.62 
OCS  2.03  0.62  0.24  1.62  1.70 
(2.31)
 5.79 
(3.08)
 16.37 
BBOT  3.72 (0.15) 0.00 (0.17) 0.00 
 0.00 
 9.92 
(7.04)
 31.80 
IMTX  3.19 (0.01)(0.01) 0.06  4.11 
(3.67)
 7.31 
(6.70)
 29.03 
TRML  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 

Dianthus Therapeutics Competitive Analysis

The better you understand Dianthus Therapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Dianthus Therapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Dianthus Therapeutics' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
DNTH ELVN TSHA SANA ATAI NKTR ANAB OCS BBOT IMTX
 4.89 
 47.48 
Dianthus
 0.29 
 28.01 
Enliven
 4.02 
 4.66 
Taysha
 2.32 
 3.79 
Sana
 9.82 
 3.58 
ATAI
 7.01 
 71.00 
Nektar
 0.63 
 54.90 
AnaptysBio
 0.14 
 28.54 
Oculis
 5.15 
 11.42 
BridgeBio
 3.41 
 9.90 
Immatics
Market Volatility
(90 Days Market Risk)
Very steady
Not too volatile
Moderately volatile
Very risky
Slightly risky
Very steady
Very steady
Very steady
Slightly risky
Somewhat reliable
Market Performance
(90 Days Performance)
Mild
Mild
Mild
Weak
Weak
Mild
Solid
Solid
Weakest
Weakest
Odds of Financial Distress
(Probability Of Bankruptcy)
High
Low
Small
High
Low
Small
Small
Fair
High
Low
Current Valuation
(Equity Enterprise Value)
Under Valued
Under Valued
Under Valued
Over Valued
Under Valued
Under Valued
Fairly Valued
Under Valued
Over Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Strong Buy
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Sell
Cautious Hold
Strong Sell
Strong Sell
Hold
Strong Sell
Strong Sell
Strong Buy
Strong Sell
Strong Sell
Current Ratio
N/A
N/A
1.79
5.09
12.25
7.14
22.79
N/A
N/A
2.95
Net Asset
374.01 M
325.76 M
160.36 M
501.02 M
159.39 M
303.85 M
483.83 M
120.35 M
194.42 M
696.15 M
Profit Margin
N/A
N/A
N/A
N/A
N/A
-1.93
-0.5
N/A
N/A
-1.42
EBITDA
(101.45 M)
(104.24 M)
(87.95 M)
(255.33 M)
(144.81 M)
(86.7 M)
(92.74 M)
(72.8 M)
(80.66 M)
34.46 M
Operating Margin
-101.74
N/A
-16.19
N/A
-37.97
-2.67
0.45
-83.52
N/A
-10.53
Current Valuation
1.79 B
1.19 B
1.03 B
957.36 M
1.29 B
960.84 M
1.16 B
1.45 B
856.64 M
891.45 M
Price To Book
4.02
3.48
5.77
5.46
8.95
13.39
114.73
9.74
N/A
2.8
Retained Earnings
(174.39 M)
(243.47 M)
(602.3 M)
(1.6 B)
(700.21 M)
(3.6 B)
(759.33 M)
(285.56 M)
(3.73 M)
(589.54 M)
Current Asset
N/A
N/A
N/A
N/A
320.15 M
350.05 M
297.84 M
N/A
N/A
N/A
Beta
1.23
1.14
1.0
1.97
1.62
1.34
0.35
0.15
N/A
1.36
Number Of Employees
78
65
73
194
54
61
136
49
81
645
Shares Outstanding
43.22 M
59.35 M
273.92 M
266.37 M
363.21 M
20.34 M
27.69 M
57.81 M
79.2 M
134.06 M
Cash Flow From Operations
(78.18 M)
(73.19 M)
(81.22 M)
(223.15 M)
(82.44 M)
(175.71 M)
(135.34 M)
(47.5 M)
(763.82 K)
(158.03 M)
Total Debt
1.49 M
15.91 M
63.18 M
94.2 M
24.71 M
102.56 M
369.46 M
1.18 M
5.71 M
16.2 M
Return On Equity
-0.29
-0.25
-0.65
-0.96
-1.01
-1.8
-3.08
-0.92
N/A
-0.3
Return On Asset
-0.19
-0.18
-0.26
-0.24
-0.29
-0.28
-0.0423
-0.33
N/A
-0.16
Number Of Shares Shorted
8.3 M
7.87 M
55.69 M
37.11 M
14.59 M
3.29 M
5.57 M
344 K
2.16 M
5.56 M
Book Value Per Share
12.75
8.03
0.8
0.75
0.66
4.33
-1.07
3.25
-403.34
4.08
Current Liabilities
N/A
N/A
N/A
N/A
74.35 M
61.25 M
16.6 M
N/A
N/A
N/A
Total Asset
374.01 M
325.76 M
160.36 M
501.02 M
159.39 M
303.85 M
483.83 M
120.35 M
194.42 M
696.15 M
Short Ratio
9.24
5.2
20.39
14.61
3.91
4.5
11.67
1.21
2.07
14.45
Target Price
72.18
41.38
11.0
8.71
12.45
123.43
67.92
46.19
24.2
19.13
Debt To Equity
N/A
N/A
1.93
0.18
0.057
0.33
0.066
N/A
N/A
0.13
Shares Owned By Institutions
96.7
91.77
97.47
78.52
26.96
74.89
93.97
45.16
51.02
79.93
Market Capitalization
2.2 B
1.66 B
1.23 B
1.03 B
1.4 B
1.35 B
1.41 B
1.67 B
1.01 B
1.33 B
Price To Earning
N/A
N/A
N/A
N/A
0.3
8.02
81.21
N/A
N/A
44.61
Price To Earnings To Growth
N/A
N/A
N/A
N/A
N/A
3.22
N/A
N/A
N/A
3.0
Price To Sales
713.64
N/A
194.48
N/A
463.35
21.55
8.29
2111.3
N/A
15.71
Net Income
(84.97 M)
(89.02 M)
(89.3 M)
(266.76 M)
(150.05 M)
(118.96 M)
(145.23 M)
(85.94 M)
7.6 M
15.22 M
Earnings Per Share
-3.5
-1.81
-0.33
-0.96
-0.83
-11.64
-2.82
-2.78
-1.11
-1.11
Shares Owned By Insiders
3.3
8.23
11.13
6.96
3.69
0.83
6.03
2.75
24.04
18.8
Revenue
6.24 M
N/A
8.33 M
N/A
308 K
98.43 M
91.28 M
686 K
N/A
155.84 M
Working Capital
262.45 M
302.21 M
115.9 M
115.38 M
55.17 M
199.89 M
386.45 M
60.66 M
139.11 M
561.57 M
Cash And Equivalents
N/A
N/A
66.24 M
484.8 M
304.06 M
546.39 M
442.15 M
N/A
N/A
324.38 M
Cash Per Share
N/A
N/A
1.61
2.57
1.83
2.91
15.66
N/A
N/A
5.0
Gross Profit
3.08 M
N/A
6.31 M
N/A
2.53 M
54.62 M
16.47 M
(54.77 M)
N/A
(91.28 M)
Day Typical Price
47.74
27.54
4.58
3.82
3.7
68.44
54.3
28.58
11.55
9.98
Accumulation Distribution
48036.87
0.0618
0.0722
92124.16
366128.0
683281.0
52203.33
4626.84
32505.19
16900.92
Market Facilitation Index
0.0
1.74
0.34
N/A
N/A
0.0
0.0
0.0
0.0
0.0
Daily Balance Of Power
(0.55)
0.046
0.5294
(0.41)
(1.08)
0.451
(0.08)
(0.1)
(0.50)
(0.44)
Period Momentum Indicator
(2.44)
0.08
0.18
(0.09)
(0.39)
4.65
(0.35)
(0.04)
(0.62)
(0.35)
Rate Of Daily Change
0.95
1.0
1.04
0.98
0.9
1.07
0.99
1.0
0.95
0.97
Day Median Price
47.87
27.3
4.54
3.83
3.76
67.16
54.0
28.6
11.62
10.03
Price Action Indicator
(1.61)
0.75
0.21
(0.09)
(0.37)
6.17
0.73
(0.09)
(0.50)
(0.30)
Coefficient Of Variation
1202.47
851.12
1531.77
7301.12
(3,387)
1264.74
410.44
440.08
(5,475)
7972.18
Mean Deviation
2.63
3.91
3.45
4.37
2.82
4.75
2.58
2.03
3.72
3.19
Jensen Alpha
0.3046
0.8589
0.1866
(0.13)
(0.19)
0.6163
0.8437
0.6202
(0.15)
(0.01)
Total Risk Alpha
(0.03)
0.216
(0.11)
(0.44)
(0.45)
(0.08)
0.541
0.396
(0.56)
(0.35)
Sortino Ratio
0.0778
0.188
0.0494
(0.0001)
N/A
0.1127
0.2352
0.2422
N/A
(0.01)
Downside Variance
9.15
17.8
18.28
23.44
N/A
26.42
10.92
5.69
N/A
18.04
Standard Deviation
3.8
7.44
4.47
5.85
3.75
8.35
3.52
2.9
5.23
4.6
Kurtosis
3.13
30.08
0.18
0.7469
0.8434
22.05
0.8891
2.08
2.45
2.56
Potential Upside
5.67
8.88
7.57
12.59
5.77
8.03
6.6
5.79
9.92
7.31
Treynor Ratio
15.3
11.9
0.209
0.0246
(0.12)
1.37
14.92
1.62
(0.17)
0.0592
Maximum Drawdown
22.93
54.92
21.14
28.66
15.3
32.58
17.62
16.37
31.8
29.03
Variance
14.44
55.34
20.02
34.25
14.05
69.66
12.39
8.4
27.39
21.14
Market Risk Adjusted Performance
15.31
11.91
0.219
0.0346
(0.11)
1.38
14.93
1.63
(0.16)
0.0692
Risk Adjusted Performance
0.0754
0.1043
0.0612
0.0197
(0.02)
0.0732
0.2056
0.1917
(0.01)
0.0184
Skewness
1.09
4.58
0.3193
0.7398
0.3609
3.81
0.1449
0.7934
0.8762
0.3667
Semi Deviation
2.66
3.67
3.95
4.63
N/A
4.9
2.63
1.7
N/A
4.11
Information Ratio
0.0619
0.1066
0.0472
(0.0001)
(0.05)
0.0694
0.2207
0.1994
(0.03)
(0.01)
Value At Risk
(4.89)
(6.94)
(6.86)
(7.71)
(5.54)
(7.77)
(5.26)
(3.08)
(7.04)
(6.70)
Expected Short fall
(3.15)
(4.48)
(3.68)
(5.63)
N/A
(5.47)
(2.97)
(2.31)
N/A
(3.67)
Downside Deviation
3.02
4.22
4.28
4.84
N/A
5.14
3.3
2.38
N/A
4.25
Semi Variance
7.1
13.48
15.62
21.41
N/A
24.03
6.92
2.9
N/A
16.88

Dianthus Therapeutics Competition Performance Charts

Five steps to successful analysis of Dianthus Therapeutics Competition

Dianthus Therapeutics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Dianthus Therapeutics in relation to its competition. Dianthus Therapeutics' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Dianthus Therapeutics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Dianthus Therapeutics' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Dianthus Therapeutics, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Dianthus Therapeutics position

In addition to having Dianthus Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run RUB Crypto Assets Thematic Idea Now

RUB Crypto Assets
RUB Crypto Assets Theme
An experimental p2p digital currency that is accepted by many vendors in Russian Ruble. The RUB Crypto Assets theme has 0 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize RUB Crypto Assets Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Dianthus Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Dianthus Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Dianthus Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Dianthus Therapeutics Stock:
How To Invest In Dianthus
Details
Is Dianthus Stock a good investment?
Details
What is Dianthus Therapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out Dianthus Therapeutics Correlation with its peers.
For more detail on how to invest in Dianthus Stock please use our How to Invest in Dianthus Therapeutics guide.
You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is there potential for Biotechnology market expansion? Will Dianthus introduce new products? Factors like these will boost the valuation of Dianthus Therapeutics. Projected growth potential of Dianthus fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about Dianthus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Dianthus Therapeutics is measured differently than its book value, which is the value of Dianthus that is recorded on the company's balance sheet. Investors also form their own opinion of Dianthus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dianthus Therapeutics' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Dianthus Therapeutics' market value can be influenced by many factors that don't directly affect Dianthus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
It's important to distinguish between Dianthus Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Dianthus Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Dianthus Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY